News | October 07, 2022
Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.
The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
MINYM can be safely used by patients above 9 years of age.
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
